Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

MiNK Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JUNE 03, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC.(NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC, OFF-THE-SHELF INVARIANT NATURAL KILLER T (INKT) CELL THERAPIES, TODAY ANNOUNCED THAT ITS ANNUAL SHAREHOLDERS MEETING WILL BEGIN AT9:30 A.M. ET. ONJUNE 17, 2026, AND WILL BE CONDUCTED IN A VIRTUAL FORMAT ONLY. REGISTRATION FOR ATTENDEES WILL START AT9:15 A.M. ET.

MINK THERAPEUTICS ANNOUNCES ITS VIRTUAL 2026 ANNUAL SHAREHOLDERS MEETING

NEW YORK AND LVIV, UKRAINE, MAY 28, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS(NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING OFF-THE-SHELF ALLOGENEIC INKT CELL THERAPIES FOR CANCER AND IMMUNE DISORDERS, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS RANDOMIZED PHASE 2 CLINICAL TRIAL EVALUATING AGENT-797 WITH STANDARD OF CARE (SOC) VS PLACEBO WITH SOC IN PATIENTS WITH SEVERE ACUTE LUNG INJURY AND CRITICAL ILLNESS.

MINK THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RANDOMIZED PHASE 2 TRIAL OF AGENT-797 IN ACUTE LUNG INJURY AND CRITICAL ILLNESS

NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RESTORE IMMUNE BALANCE AND TREAT IMMUNE-MEDIATED DISEASES AND CANCER, TODAY ANNOUNCED NEW CLINICAL AND TRANSLATIONAL DATA PRESENTED AT THE AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE 2026 AND THE SIMULTANEOUS PUBLICATION IN CLINICAL IMMUNOLOGY COMMUNICATIONS 1 DESCRIBING THE USE OF SEQUENTIAL IMMUNOTHERAPY WITH MINK'S OFF-THE-SHELF INKT CELL THERAPY, AGENT-797 AND N-803, AN IL-15 SUPERAGONIST, IN A CRITICALLY ILL PATIENT WITH UNRESOLVING DISSEMINATED COCCIDIOIDES IMMITIS INFECTION, SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME, AND CONCURRENT HOSPITAL-ACQUIRED PSEUDOMONAS AERUGINOSA PNEUMONIA.

MINK THERAPEUTICS REPORTS NEW DATA ON AGENT-797, AN ALLO-INKT CELL THERAPY AT ATS 2026; SIMULTANEOUSLY PUBLISHED IN CLINICAL IMMUNOLOGY COMMUNICATIONS

RANDOMIZED PHASE 2 TRIAL INITIATED FOR AGENT-797 IN SEVERE ACUTE LUNG INJURY AND RESPIRATORY DISTRESS, WITH PRELIMINARY DATA EXPECTED IN THE SECOND HALF OF 2026 AACR AND ASGCT PRESENTATIONS SHOWCASE DURABLE SURVIVAL AND CONTEXT-DEPENDENT INKT ACTIVITY IN CANCER AND INFLAMMATORY LUNG DISEASE NON-DILUTIVE COLLABORATIONS EXPAND MINK'S PLATFORM AND POTENTIATE MEANINGFUL COMMERCIAL REVENUE POTENTIAL, WHILE PRESERVING FOCUS ON LEAD CLINICAL PROGRAMS COMPANY CONTINUES DISCIPLINED EXECUTION WITH REDUCED OPERATING BURN AND FOCUSED ADVANCEMENT OF HIGH-PRIORITY PROGRAMS NEW CLINICAL DATA TO BE PRESENTED AT THE ATS CONFERENCE ON MAY 20, 2026 NEW YORK, MAY 15, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RESTORE IMMUNE BALANCE AND TREAT IMMUNE-MEDIATED DISEASES AND CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDING MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. MINK ENTERED 2026 FOCUSED ON CONVERTING A GROWING BODY OF CLINICAL AND TRANSLATIONAL EVIDENCE INTO PROSPECTIVE VALIDATION, SAID JENNIFER BUELL, PH.D.

MINK THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND ADVANCES INKT CELL THERAPY PLATFORM INTO RANDOMIZED CLINICAL VALIDATION

NEW YORK AND LVIV, UKRAINE, MAY 14, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING OFF-THE-SHELF ALLOGENEIC INKT CELL THERAPIES FOR CANCER AND IMMUNE DISORDERS, AND FIRST LVIV TERRITORIAL MEDICAL UNION TODAY ANNOUNCED THE INITIATION OF A RANDOMIZED PHASE 2 CLINICAL TRIAL EVALUATING AGENT-797, MINK'S OFF-THE-SHELF ALLOGENEIC INVARIANT NATURAL KILLER T CELL THERAPY (INKTS), IN PATIENTS WITH SEVERE ACUTE LUNG INJURY (ALI). THE STUDY HAS RECEIVED AUTHORIZATION FROM THE MINISTRY OF HEALTH OF UKRAINE AND IS SUPPORTED BY AN ACTIVE U.S. IND.

MINK THERAPEUTICS AND FIRST LVIV TERRITORIAL MEDICAL UNION INITIATE RANDOMIZED PHASE 2 TRIAL OF AGENT-797 IN ACUTE LUNG INJURY AND CRITICAL ILLNESS

NEW YORK, MAY 12, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELL THERAPIES FOR CANCER AND IMMUNE DISORDERS, TODAY ANNOUNCED DATA BEING PRESENTED AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY ANNUAL MEETING (ASGCT 2026) IN BOSTON, MASSACHUSETTS. THE DATA DEMONSTRATE THAT AGENT-797, MINK'S OFF-THE-SHELF, ALLOGENEIC INKT CELL THERAPY PRODUCES FUNDAMENTALLY DIFFERENT, DISEASE-APPROPRIATE IMMUNE RESPONSES IN PATIENTS WITH SOLID TUMORS AND PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS), DRIVEN BY THE INTRINSIC BIOLOGY OF INKT CELLS RATHER THAN GENETIC MODIFICATION.

MINK THERAPEUTICS PRESENTS CLINICAL EVIDENCE THAT A SINGLE, OFF-THE-SHELF, INKT CELL PRODUCT DRIVES CONTEXT-DEPENDENT IMMUNE RESPONSES AT ASGCT 2026

NEW YORK, MAY 08, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELL THERAPIES TO TREAT CANCER AND IMMUNE DISORDERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, BEFORE THE MARKET OPENS ON FRIDAY, MAY 15, 2026.

MINK THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHT PLATFORM PROGRESS ACROSS INKT CELL THERAPY PROGRAMS

NEW YORK, APRIL 03, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC.(NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RESTORE IMMUNE BALANCE AND TREAT IMMUNE-MEDIATED DISEASES AND CANCER, TODAY ANNOUNCED THAT DATA FROM AN INVESTIGATOR-INITIATED PHASE II TRIAL AT MEMORIAL SLOAN KETTERING CANCER CENTER, EVALUATING AGENT-797, MINK'S ALLO-INKT CELL THERAPY, IN COMBINATION WITH BOTENSILIMAB (BOT) AND BALSTILIMAB (BAL), WILL BE PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, TAKING PLACE APRIL 17-22, 2026, IN SAN DIEGO, CA.

MINK THERAPEUTICS AND MEMORIAL SLOAN KETTERING TO PRESENT PHASE II STUDY OF AGENT-797 COMBINATION IN PD-1 REFRACTORY GASTROESOPHAGEAL CANCER AT AACR 2026

NEW YORK, APRIL 01, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC.(NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RESTORE IMMUNE BALANCE AND TREAT IMMUNE-MEDIATED DISEASES AND CANCER, TODAY ANNOUNCED THAT AN ABSTRACT FEATURING ITS INVESTIGATIONAL INKT CELL THERAPY, AGENT-797, HAS BEEN ACCEPTED FOR PRESENTATION AT THE ATS INTERNATIONAL CONFERENCE 2026 OCCURRING MAY 15-20, 2026 IN ORLANDO, FLORIDA.

MINK THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTANCE FOR PRESENTATION AT THE AMERICAN THORACIC SOCIETY (ATS) 2026 INTERNATIONAL CONFERENCE

NEW YORK, MARCH 31, 2026 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RESTORE IMMUNE BALANCE AND TREAT IMMUNE-MEDIATED DISEASES AND CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025.

MiNK Therapeutics, Inc.

INKT

Price

Financial Reports

No items found.

Press Releases

MiNK Therapeutics, Inc.

INKT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INKT